CEL SCI CORP — Investor Relations & Filings
CEL-SCI Corporation is a clinical-stage biotechnology company engaged in the research and development of immunotherapies for cancer, autoimmune, and infectious diseases. Its lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is a neoadjuvant treatment designed to stimulate a patient's immune system to fight cancer before standard treatments like surgery, radiation, and chemotherapy are administered. The company has completed a global pivotal Phase III clinical trial for Multikine in patients with advanced primary, previously untreated squamous cell carcinoma of the head and neck. The study demonstrated a significant 5-year overall survival benefit in a specific patient subgroup. CEL-SCI is also developing its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for potential treatments of autoimmune and infectious diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | |
| S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | |
| 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | |
| 4 Filing | 2026-01-26 | English | |
| 4 Filing | 2026-01-05 | English | |
| 4 Filing | 2026-01-05 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39639190 | S-1/A - CEL SCI CORP (0000725363) (Filer) | 2026-05-01 | English | ||
| 34662842 | S-1 - CEL SCI CORP (0000725363) (Filer) | 2026-04-17 | English | ||
| 32880286 | 10-Q - CEL SCI CORP (0000725363) (Filer) | 2026-02-17 | English | ||
| 18269065 | 4 Filing | 2026-01-26 | English | ||
| 18269090 | 4 Filing | 2026-01-05 | English | ||
| 18269058 | 4 Filing | 2026-01-05 | English | ||
| 18269037 | 4 Filing | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 18269100 | 10-K Filing | 2025-12-29 | English | ||
| 9417629 | PRIMARY DOCUMENT | 2025-12-05 | English | ||
| 9417630 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 9417631 | FORM 8-K | 2025-11-24 | English | ||
| 9417632 | FORM S-3 | 2025-11-07 | English | ||
| 9417635 | FORM 8-K | 2025-11-05 | English | ||
| 9417633 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
| 9417634 | PRIMARY DOCUMENT | 2025-10-02 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CALIWAY BIOPHARMACEUTICALS CO., LTD.
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
CEL SCI CORP via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34401/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34401 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34401 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34401 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34401}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CEL SCI CORP (id: 34401)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.